DPP-4 Inhibitors Drug-Drug Interaction Table

What Is the DPP-4 Inhibitor Drug Class?

DPP-4 inhibitors block the dipeptidyl peptidase-4 enzyme, which normally degrades incretin hormones GLP-1 and GIP within minutes of secretion. By inhibiting this enzyme, these agents roughly double endogenous active GLP-1 concentrations, stimulating glucose-dependent insulin release and suppressing glucagon, only when blood glucose is elevated. This glucose-dependent mechanism explains the low standalone hypoglycemia risk.

Approved Agents and Basic Pharmacology

Four single-entity DPP-4 inhibitors hold FDA approval for type 2 diabetes in the United States:

| Drug | Dose (standard) | Elimination route | Half-life | |---|---|---|---| | Sitagliptin (Januvia) | 100 mg once daily | Renal (87% unchanged) | ~12 h | | Saxagliptin (Onglyza) | 5 mg once daily | Hepatic CYP3A4/5 + renal | ~2.5 h (active metabolite ~3.1 h) | | Alogliptin (Nesina) | 25 mg once daily | Renal (76% unchanged) | ~21 h | | Linagliptin (Tradjenta) | 5 mg once daily | Biliary/fecal (~90%) | ~12 h |

Linagliptin is the only member eliminated primarily through the bile, making it the preferred choice when eGFR is below 30 mL/min/1.73 m² without any dose adjustment [1].

Selectivity and Binding Characteristics

All four agents are highly selective for DPP-4 over related enzymes DPP-8 and DPP-9, selectivity ratios exceeding 2,500-fold for sitagliptin in preclinical studies [2]. This selectivity matters because DPP-8/9 inhibition in animals produces GI toxicity and immune effects not seen with therapeutic DPP-4 doses. Saxagliptin forms a covalent but slowly reversible bond with the DPP-4 active site, giving it a pharmacodynamic duration longer than its short plasma half-life suggests.

Efficacy Benchmarks

In the TECOS trial (N=14,671), sitagliptin added to usual care reduced HbA1c by 0.29% more than placebo at 1 year while keeping cardiovascular event rates equivalent [3]. Earlier placebo-controlled monotherapy data place HbA1c reductions at 0.5 to 0.8% across class members, with responses attenuated at lower baseline HbA1c values [4].

DPP-4 Inhibitors Drug-Drug Interaction Table

The DDI profile of gliptins is narrow compared with most oral antidiabetics, but several interactions carry direct clinical consequences, particularly with saxagliptin.

Saxagliptin: CYP3A4/5 Interactions

Saxagliptin is the only class member substantially metabolized by CYP3A4/5. Co-administration with strong CYP3A4/5 inhibitors approximately doubles saxagliptin exposure. The FDA-approved label mandates a dose reduction to 2.5 mg/day when saxagliptin is prescribed alongside strong inhibitors [5].

Strong CYP3A4/5 inhibitors requiring the 2.5 mg dose cap:

• Ketoconazole (AUC of saxagliptin increased 2.5-fold in pharmacokinetic studies per the FDA label [5])
• Itraconazole, voriconazole, posaconazole
• Clarithromycin, telithromycin
• Ritonavir, atazanavir, indinavir, nelfinavir, saquinavir
• Nefazodone

Strong CYP3A4/5 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) reduce saxagliptin exposure and may diminish glycemic effect, though the label does not specify a dose increase, clinicians should monitor HbA1c more closely.

Full Class DDI Reference Table

| Interacting Drug / Class | DPP-4 Agent(s) Affected | Mechanism | Clinical Effect | Management | |---|---|---|---|---| | Strong CYP3A4/5 inhibitors (ketoconazole, ritonavir, clarithromycin) | Saxagliptin | CYP3A4/5 inhibition | Saxagliptin AUC up ~2.5x | Cap saxagliptin at 2.5 mg/day [5] | | Strong CYP3A4/5 inducers (rifampin, carbamazepine) | Saxagliptin | CYP3A4/5 induction | Saxagliptin AUC reduced | Monitor HbA1c; consider alternative agent | | Sulfonylureas (glipizide, glimepiride, glyburide) | All | Additive insulin secretion | Hypoglycemia risk increased | Reduce sulfonylurea dose; counsel patient | | Insulin (basal or prandial) | All | Additive glucose-lowering | Hypoglycemia risk increased | Reduce insulin dose by 10 to 20% if adding DPP-4i | | Digoxin | Sitagliptin | P-glycoprotein transporter | Digoxin AUC up ~11% at steady state [2] | Monitor digoxin levels; likely clinically minor | | Metformin | All | No pharmacokinetic interaction | No AUC change; additive pharmacodynamic effect | No dose adjustment needed | | Cyclosporine | Saxagliptin | P-gp and CYP3A4 inhibition | Saxagliptin exposure increased | Treat as strong CYP3A4 inhibitor; cap 2.5 mg | | ACE inhibitors (lisinopril, ramipril) | All | Both raise bradykinin levels | Theoretical additive angioedema risk | Monitor; baseline angioedema is a contraindication to DPP-4i | | Corticosteroids (systemic) | All | Pharmacodynamic antagonism | Hyperglycemia; blunts glucose-lowering | Increase monitoring; temporary dose adjustment of DPP-4i rarely needed | | Fluconazole (moderate CYP3A4 inhibitor) | Saxagliptin | Partial CYP3A4 inhibition | Modest saxagliptin exposure increase | No dose change required; monitor | | Warfarin | Sitagliptin | Minor CYP2C9 competition | INR may change slightly | Monitor INR with initiation or dose changes | | Alcohol | All | Pharmacodynamic | Enhanced hypoglycemia if combined with SU/insulin | Counsel patients |

ACE Inhibitor and Angioedema: A Practical Note

Both DPP-4 inhibitors and ACE inhibitors raise bradykinin. The combination does not produce a pharmacokinetic interaction, but a pooled analysis of saxagliptin and alogliptin trials found numerically higher rates of angioedema in patients on concurrent ACE inhibitor therapy [6]. The absolute numbers remain small. A prior history of ACE inhibitor-induced angioedema is listed as a contraindication to the entire DPP-4 inhibitor class in prescribing information [5].

Renal Dosing for Each Agent

Renal impairment affects three of the four agents materially. Getting the dose wrong in chronic kidney disease leads to drug accumulation and, in the case of sitagliptin and alogliptin, increased adverse event exposure.

Sitagliptin Renal Dose Table

| eGFR (mL/min/1.73 m²) | Sitagliptin Dose | |---|---| | ≥45 | 100 mg once daily | | 30 to <45 | 50 mg once daily | | <30 (including ESRD on dialysis) | 25 mg once daily |

Sitagliptin is dialyzable. On dialysis days, administer after the session [1].

Saxagliptin Renal Dose Table

| eGFR (mL/min/1.73 m²) | Saxagliptin Dose | |---|---| | >45 | 5 mg once daily | | ≤45 | 2.5 mg once daily | | ESRD on hemodialysis | 2.5 mg after dialysis |

The FDA label also advises against initiating saxagliptin in patients with eGFR <15 mL/min/1.73 m² due to limited data [5].

Alogliptin Renal Dose Table

| eGFR (mL/min/1.73 m²) | Alogliptin Dose | |---|---| | ≥60 | 25 mg once daily | | 30 to <60 | 12.5 mg once daily | | <30 (including ESRD) | 6.25 mg once daily |

Linagliptin: No Renal Adjustment

Linagliptin requires no dose modification regardless of eGFR, including in patients on hemodialysis. Its biliary elimination makes it the practical default for patients with CKD stage 4 or 5 [1].

Cardiovascular Safety Evidence

The FDA issued a December 2008 guidance requiring cardiovascular outcome trials (CVOTs) for all new antidiabetic drugs. All four DPP-4 inhibitors have completed large-scale CVOTs.

SAVOR-TIMI 53: Saxagliptin

SAVOR-TIMI 53 (N=16,492, median follow-up 2.1 years) found saxagliptin non-inferior to placebo for the primary 3-point MACE outcome. However, hospitalization for heart failure (HHF) occurred in 3.5% of the saxagliptin group versus 2.8% in the placebo group (hazard ratio 1.27; 95% CI 1.07 to 1.51; P<0.001 for non-inferiority, P=0.007 for HHF superiority of placebo) [7]. The ADA Standards of Medical Care in Diabetes caution against saxagliptin in patients with existing heart failure or at high HHF risk [8].

TECOS: Sitagliptin

TECOS (N=14,671, median follow-up 3.0 years) found no significant difference in MACE, HHF, or renal outcomes between sitagliptin and placebo. HHF rates were 3.1% versus 3.1% [3]. This neutral HHF finding distinguishes sitagliptin from saxagliptin in the risk-benefit calculus for patients with cardiac history.

EXAMINE: Alogliptin

EXAMINE (N=5,380, patients with recent acute coronary syndrome) found alogliptin non-inferior to placebo for MACE. HHF was numerically higher with alogliptin (3.9% vs. 3.3%), though the trial was not powered for this endpoint [9]. The FDA subsequently added an HHF warning to alogliptin's label.

CARMELINA: Linagliptin

CARMELINA (N=6,979, high CV and renal risk population, median follow-up 2.2 years) showed non-inferiority for MACE with no signal for increased HHF (4.9% vs. 4.9%) [10]. This CV neutrality and the absence of renal dose adjustment support linagliptin as a reasonable choice in diabetic kidney disease.

Pancreatitis and Pancreatic Cancer: Putting the Signal in Context

The FDA issued a safety communication in 2013 reviewing reports of acute pancreatitis and pre-neoplastic pancreatic lesions associated with incretin-based therapies [11]. Mechanistic concern arose from animal data showing pancreatic duct cell proliferation.

Clinical Data Review

A 2014 meta-analysis of 55 randomized trials (N=117,411 patient-years) found no statistically significant increase in pancreatitis with DPP-4 inhibitors (OR 1.79; 95% CI 0.96 to 3.34), acknowledging that the absolute event rate was low enough that individual trials were underpowered to detect a signal [12]. The four large CVOTs described above, with a combined follow-up exceeding 70,000 patient-years, did not show a statistically significant excess of acute pancreatitis.

Prescriber Guidance

The prescribing information for all four agents includes a warning to discontinue if acute pancreatitis is confirmed. Do not rechallenge after a confirmed episode. Patients with a history of pancreatitis were excluded from most registration trials, so no safety data exist in this subgroup.

Practical Prescribing: Choosing Among Agents

The four agents share a mechanism but differ enough in elimination, DDI burden, and CV evidence to make agent selection non-trivial.

Decision Framework by Patient Characteristic

Patient has CKD stage 4 or 5 (eGFR <30): Use linagliptin 5 mg. No dose calculation required, and CARMELINA confirms safety in this population [10].

Patient is on a strong CYP3A4 inhibitor (e.g., ritonavir-boosted HIV regimen): Avoid saxagliptin or cap at 2.5 mg per label [5]. Sitagliptin, alogliptin, or linagliptin carry no CYP3A4 DDI.

Patient has established heart failure (HFrEF or HFpEF): Avoid saxagliptin based on SAVOR-TIMI 53 HHF data [7]. The ADA 2024 Standards recommend SGLT2 inhibitors first in this population regardless; if an add-on DPP-4i is needed, sitagliptin or linagliptin have cleaner HHF records [8].

Patient is on an ACE inhibitor and has a prior angioedema episode: The entire DPP-4 inhibitor class is contraindicated. Switch to a different second-line agent.

Patient needs the lowest DDI burden (polypharmacy, transplant): Linagliptin and sitagliptin have the most favorable DDI profiles. Linagliptin has virtually no significant pharmacokinetic DDIs documented in its label [1].

Elderly patient with fluctuating renal function: Linagliptin avoids the need to recalculate doses as eGFR changes. This practical advantage often outweighs minor cost considerations in the long-term care setting.

Adverse Effects Beyond Hypoglycemia

Nasopharyngitis and Upper Respiratory Infections

Class-wide pooled data consistently show a 1 to 2% absolute increase in upper respiratory infection rates versus placebo. The mechanism may relate to DPP-4's role in T-cell activity and immune function. A 2006 mechanistic review noted that DPP-4 is expressed on CD26+ lymphocytes and may modulate lymphocyte homing [2]. Clinical relevance is low for most patients.

Joint Pain

The FDA issued a drug safety communication in August 2015 noting reports of severe and disabling arthralgia associated with DPP-4 inhibitors [13]. The onset ranged from one day to years after starting treatment, and symptoms resolved with discontinuation in most cases. This reaction appears to be class-wide and idiosyncratic. Consider discontinuation if a patient develops unexplained severe joint pain without another cause.

Bullous Pemphigoid

Post-marketing surveillance has identified an association between DPP-4 inhibitor use and bullous pemphigoid, an autoimmune blistering skin condition. A 2018 pharmacovigilance analysis found a statistically significant disproportionality signal across all four agents [14]. Dermatology referral and drug discontinuation are appropriate when this diagnosis is confirmed.

Drug Interactions With Combination Tablets

Sitagliptin is available co-formulated with metformin (Janumet), metformin XR (Janumet XR), and ertugliflozin (Steglujan). Saxagliptin is co-formulated with metformin (Kombiglyze XR) and dapagliflozin (Qtern). Linagliptin is available with metformin (Jentadueto) and empagliflozin (Glyxambi).

When prescribing a combination product, the DDI obligations of each component apply independently. A patient on Qtern (saxagliptin/dapagliflozin) who begins ritonavir still requires the saxagliptin 2.5 mg cap, but the fixed combination forces discontinuation of Qtern and separate prescribing of dapagliflozin plus saxagliptin 2.5 mg. Communicating this to pharmacy teams reduces dispensing errors.